153 related articles for article (PubMed ID: 8877768)
21. Review of an inactivated vaccine against hantaviruses.
Cho HW; Howard CR; Lee HW
Intervirology; 2002; 45(4-6):328-33. PubMed ID: 12602351
[TBL] [Abstract][Full Text] [Related]
22. [Safety and immunogenicity of inactivated bivalent EHF vaccine in humans].
Liu W; Xu X; Ruan Y; Weng S; Liu W; Zhou W; Dong G; Gu H; Zhu Z; Xu Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Dec; 21(6):445-7. PubMed ID: 11860832
[TBL] [Abstract][Full Text] [Related]
23. Preliminary human trial of inactivated golden hamster kidney cell (GHKC) vaccine against haemorrhagic fever with renal syndrome (HFRS).
Song G; Huang YC; Hang CS; Hao FY; Li DX; Zheng XL; Liu WM; Li SL; Huo ZW; Huei LJ
Vaccine; 1992; 10(4):214-6. PubMed ID: 1348595
[TBL] [Abstract][Full Text] [Related]
24. Pathogenicity of novel hantavirus isolate and antigenicity and immunogenicity of novel strain-based inactivated vaccine.
Liu YY; Xu YQ; Zhong Y; Wei F; Ling JX; Li JL; Yang L; Quan FY; Chen SL; Luo F; Hou W; Yang ZQ; Chen LJ; Xiong HR
Vaccine; 2023 Nov; 41(49):7482-7490. PubMed ID: 37953099
[TBL] [Abstract][Full Text] [Related]
25. Protective Effectiveness of Inactivated Hantavirus Vaccine Against Hemorrhagic Fever With Renal Syndrome.
Jung J; Ko SJ; Oh HS; Moon SM; Song JW; Huh K
J Infect Dis; 2018 Apr; 217(9):1417-1420. PubMed ID: 29373686
[TBL] [Abstract][Full Text] [Related]
26. [The changes in serum antibody level after immunization with HFRS vaccine].
Gong Z; Weng J; Zhao Z; Lan J; Chen Y; Lin C; Fu G; Zhu Z; Xia J; Ji Q; Xu J; Wang C; Yu X; Wang W; Fang C
Zhonghua Yu Fang Yi Xue Za Zhi; 2000 Nov; 34(6):351-3. PubMed ID: 11860948
[TBL] [Abstract][Full Text] [Related]
27. Puumala and Dobrava viruses cause hemorrhagic fever with renal syndrome in Bosnia-Herzegovina: evidence of highly cross-neutralizing antibody responses in early patient sera.
Lundkvist A; Hukic M; Hörling J; Gilljam M; Nichol S; Niklasson B
J Med Virol; 1997 Sep; 53(1):51-9. PubMed ID: 9298732
[TBL] [Abstract][Full Text] [Related]
28. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome.
Boudreau EF; Josleyn M; Ullman D; Fisher D; Dalrymple L; Sellers-Myers K; Loudon P; Rusnak J; Rivard R; Schmaljohn C; Hooper JW
Vaccine; 2012 Mar; 30(11):1951-8. PubMed ID: 22248821
[TBL] [Abstract][Full Text] [Related]
29. [Actual problems of hemorrhagic fever with renal syndrome].
Tkachenko EA; bernshtein AD; Dzagurova TK; Morozov VG; Slonova RA; Ivanov LI; Trankvilevskiĭ DV; Kruger D
Zh Mikrobiol Epidemiol Immunobiol; 2013; (1):51-8. PubMed ID: 23805652
[TBL] [Abstract][Full Text] [Related]
30. Serological evidence of Hantaan virus infection in the United States.
Yanagihara R; Chin CT; Weiss MB; Gajdusek DC; Diwan AR; Poland JB; Kleeman KT; Wilfert CM; Meiklejohn G; Glezen WP
Am J Trop Med Hyg; 1985 Mar; 34(2):396-9. PubMed ID: 2858988
[TBL] [Abstract][Full Text] [Related]
31. Pre-Clinical Studies of Inactivated Polyvalent HFRS Vaccine.
Dzagurova TK; Siniugina AA; Ishmukhametov AA; Egorova MS; Kurashova SS; Balovneva MV; Deviatkin AA; Tkachenko PE; Leonovich OA; Tkachenko EA
Front Cell Infect Microbiol; 2020; 10():545372. PubMed ID: 33251155
[TBL] [Abstract][Full Text] [Related]
32. Hantavirus Gc induces long-term immune protection via LAMP-targeting DNA vaccine strategy.
Jiang DB; Zhang JP; Cheng LF; Zhang GW; Li Y; Li ZC; Lu ZH; Zhang ZX; Lu YC; Zheng LH; Zhang FL; Yang K
Antiviral Res; 2018 Feb; 150():174-182. PubMed ID: 29273568
[TBL] [Abstract][Full Text] [Related]
33. Persistence of immune responses to vaccine against haemorrhagic fever with renal syndrome in healthy adults aged 16-60 years: results from an open-label2-year follow-up study.
Zheng Y; Zhou BY; Wei J; Xu Y; Dong JH; Guan LY; Ma P; Yu PB; Wang JJ
Infect Dis (Lond); 2018 Jan; 50(1):21-26. PubMed ID: 28703073
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic rapid tests for acute hantavirus infections: specific tests for Hantaan, Dobrava and Puumala viruses versus a hantavirus combination test.
Hujakka H; Koistinen V; Kuronen I; Eerikäinen P; Parviainen M; Lundkvist A; Vaheri A; Vapalahti O; Närvänen A
J Virol Methods; 2003 Mar; 108(1):117-22. PubMed ID: 12565162
[TBL] [Abstract][Full Text] [Related]
35. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection.
Hooper JW; Kamrud KI; Elgh F; Custer D; Schmaljohn CS
Virology; 1999 Mar; 255(2):269-78. PubMed ID: 10069952
[TBL] [Abstract][Full Text] [Related]
36. [Development of ELISA on the basis of monoclonal antibodies for detecting specific activity of the vaccine against hemorrhagic fever with renal syndrome].
Dzagurova TK; Solopova ON; Sveshnikov PG; Korotina NA; Balovneva MV; Leonovich OA; Varlamov NE; Malkin GA; Sotskova SE; Tkachenko EA
Vopr Virusol; 2013; 58(1):40-4. PubMed ID: 23785761
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of subclinical infection rates between vaccinated group with type I inactivated vaccine against hemorrhagic fever and controls].
Ruan Y; Xu X; Shao S; Tong Z; Weng S; Zhou W; Gu H; Zhu Z; Xu Z
Zhonghua Yu Fang Yi Xue Za Zhi; 1999 Sep; 33(5):308-10. PubMed ID: 11864500
[TBL] [Abstract][Full Text] [Related]
38. Hemorrhagic fever with renal syndrome caused by the Seoul virus.
Kim YS; Ahn C; Han JS; Kim S; Lee JS; Lee PW
Nephron; 1995; 71(4):419-27. PubMed ID: 8587622
[TBL] [Abstract][Full Text] [Related]
39. Epidemiological investigations following an outbreak of hemorrhagic fever with renal syndrome in Greece.
LeDuc JW; Antoniades A; Siamopoulos K
Am J Trop Med Hyg; 1986 May; 35(3):654-9. PubMed ID: 2871769
[TBL] [Abstract][Full Text] [Related]
40. DNA vaccines for HFRS: laboratory and clinical studies.
Schmaljohn CS; Spik KW; Hooper JW
Virus Res; 2014 Jul; 187():91-6. PubMed ID: 24370868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
